The findings come from the largest meta-analysis so far of 113 observational studies, published online April 16 in the Annals of Oncology. “The present meta-analysis provides further evidence and quantification of a favorable effect of aspirin on colorectal and other digestive tract neoplasms [and] it also suggests that the protection tends to increase with longer duration of use, and for colorectal, with increasing dose,” conclude the authors, led by Cristina Bosetti, PhD, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy. Read more . . .
Regular use of aspirin has once again been linked to a reduced risk of cancer, this time showing a significantly reduced risk of cancer at all sites within the gastrointestinal (GI) tract, including pancreatic and liver cancer, which are too often fatal.